

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities of the Company.*



**VIVA BIOTECH HOLDINGS**

**维亚生物科技控股集团**

*(Incorporated in the Cayman Islands as an exempted company with limited liability)*

**(Stock code: 1873)**

**MAJOR TRANSACTION**  
**GRANT OF WAIVER FROM STRICT COMPLIANCE WITH RULE 14.41(A) OF**  
**THE LISTING RULES AND DELAY IN DISPATCH OF CIRCULAR**

Reference is made to Viva Biotech Holdings' (the "**Company**") announcement dated September 21, 2020 in relation to the acquisition of the entire equity interest in SYNthesis med chem (Hong Kong) Limited for approximately US\$80 million (the "**Announcement**"). Capitalized terms used herein have the same meanings as defined in the Announcement unless the context requires otherwise.

As the Acquisition is approved by way of written Shareholders' approval, as disclosed in the Announcement, pursuant to Rule 14.41(a) of the Listing Rules, a circular of the Company (the "**Circular**") containing, among other things: (i) further details of the Acquisition; (ii) financial information of the Company; (iii) financial information of the Target Company; and (iv) other information as required under the Listing Rules, is required to be dispatched to the Shareholders within 15 business days after the publication of the Announcement (which was October 13, 2020) and the Company would apply for a waiver from strict compliance with Rule 14.41(a) of the Listing Rules (the "**Waiver**") from the Stock Exchange such that the dispatch date of the Circular can be postponed to a date more than 15 business days after publication of the Announcement.

After consulting with the professional advisers involved in the preparation of the Circular, including Ernst & Young, the reporting accountants of the Company, the Company believes that additional time will be required for preparation of historical financial information, performing audit work and other procedures as (a) Ernst & Young only had full access to the Target Company's books and accounts after the Company entered into the agreement for the Acquisition; (b) the Target Company has a number of subsidiaries incorporated across a number of jurisdictions; and (c) the PRC national day holiday break has also slowed down the work on the preparation of the financial information to be included in the Circular.

The Company is pleased to announce that the Stock Exchange has granted a Waiver on October 15, 2020 on the condition that the Company will dispatch the Circular to the Shareholders on or before December 15, 2020. The Stock Exchange may withdraw or change such waiver if the Company's situation changes.

By order of the Board  
**Viva Biotech Holdings**  
**Mao Chen Cheney**  
*Chairman and Chief Executive Officer*

Hong Kong, October 15, 2020

*As at the date of this announcement, the Board comprises four Executive Directors, namely, Mr. Mao Chen Cheney (Chairman), Mr. Wu Ying, Mr. Hua Fengmao and Mr. Ren Delin; two Non-executive Directors, namely, Ms. Mao Jun and Ms. Sun Yanyan; and three Independent Non-executive Directors, namely, Mr. Fu Lei, Ms. Li Xiangrong and Mr. Wang Haiguang.*